CytomX - ein bahnbrechender Ansatz in der Tumortherapie (Seite 21)
eröffnet am 01.07.16 16:03:16 von
neuester Beitrag 01.05.24 17:27:40 von
neuester Beitrag 01.05.24 17:27:40 von
Beiträge: 1.462
ID: 1.234.534
ID: 1.234.534
Aufrufe heute: 19
Gesamt: 164.145
Gesamt: 164.145
Aktive User: 0
ISIN: US23284F1057 · WKN: A14158 · Symbol: 6C1
4,1000
EUR
-0,58 %
-0,0240 EUR
Letzter Kurs 17:12:21 Tradegate
Neuigkeiten
02.05.24 · wO Chartvergleich |
02.05.24 · Sharedeals |
01.05.24 · globenewswire  |
08.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8500 | +35,04 | |
| 4,9700 | +20,60 | |
| 0,8232 | +17,25 | |
| 1,9748 | +16,48 | |
| 1,0900 | +15,96 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5000 | -26,24 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Vor dem 4. Quartal wird sich wahrscheinlich nichts mehr tun, da vorher keine News zu erwarten sind.
Wenn das hier so weiter geht sehen wir ein neues 52 Wochen tief.
CytomX
Der Kurs kommt nicht richtig in Schwung. Wie ist Eure Einschätzung wie wird sich der Kurs die nächsten Monate entwickeln?
CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research
https://ir.cytomx.com/news-releases/news-release-details/cyt…
https://ir.cytomx.com/news-releases/news-release-details/cyt…
Trading Spotlight
https://seekingalpha.com/article/4434506-checking-in-on-cyto…
Checking In On CytomX Therapeutics
Jun. 13, 2021 5:01 AM ETCytomX Therapeutics, Inc. (CTMX)
Summary
Today, we revisit CytomX Therapeutics for our first in-depth look at this small oncology name since August of 2019.
The company is well funded at the moment, has strategic partnerships and a few 'shots on goal'.
A full investment analysis and recommendation follows in the paragraphs below.
I do much more than just articles at The Biotech Forum: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Set iv fluid intravenous drop saline drip hospital room,Medical Concept,treatment emergency and injection drug infusion care chemotherapy, concept.blue light background,selective focus stock photo
Amornrat Phuchom/iStock via Getty Images
It's easy finding reasons why other folks should be patient.”― George Eliot, Adam Bede
Today, we revisit a small oncology concern for the first time in over two and a half years. Given the time elapsed since out last in-depth look at this developmental firm, it was time for a new deep dive. A full analysis follows.
Company Overview:
CytomX Therapeutics (CTMX) is a San Francisco, California-based clinical-stage oncology-oriented biopharmaceutical company that IPO’d in 2015. The company’s pipeline is based around their Probody therapeutic design. Probody therapeutics seek to manipulate the tumor microenvironment to better localize treatment and limit the effect on healthy tissue. The therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment, and masked target-binding regions limit activity in healthy tissue. When the therapeutics encounter active proteases near a tumor, they remove their masks and bind to the tumor targets, ultimately turning the disease against itself.
Overall, this new therapeutic design can create or widen the therapeutic window, enable new combinations previously not possible due to toxicities, and expand the universe of drug targets. The pipeline of Probody therapeutics consists of 9 product candidates; however, the overall pipeline is in the early innings of development. The company’s two lead product candidates are CX-2009 and CX-2029. CytomX Therapeutics currently has a market capitalization of approximately $450 million and trades for just north of $7.00 a share.
Pipeline:
Source: January Presentation
CX-2009:
CX-2009 is a Probody drug conjugate that is conjugated with DM4, targeting CD166. CD166 is a molecule widely and highly expressed on solid tumor cells and in HER2 non-amplified breast cancer. Nearly 80% of breast cancer is HER2 non-amplified. CD166 was previously considered undruggable due to its expression on normal tissues. The drug is being tested as a monotherapy in ER/PR positive, HER2 negative breast cancer, and also as a combination therapy in triple-negative breast cancer. Breast cancer is the 2nd leading cause of cancer deaths in women. It’s estimated that breast cancer is 30% of all cancer in females with roughly 276,000 new cases a year in the United States. Furthermore, approximately 42,000 women die each year in the United States. In updated Phase 1 trial results, announced at ASCO in 2020, the drug demonstrated durable clinical activity in HER2 negative breast cancer.
Source: January Presentation
Clinical activity for the program continues to progress. CytomX began enrolling patients with human epidermal growth factor receptor 2 HER2-non-amplified breast cancer into a Phase 2 multi-cohort study evaluating CX-2009 as monotherapy, and as a combination treatment paired with CX-072, a conditionally activated anti-PD-L1 antibody, in patients with triple-negative breast cancer. Initial data from the CX-2009 Phase 2 study should be available in the fourth quarter of 2021.
Source: January Presentation
CX-2029:
CX-2029 is a PDC directed against CD71. CD71 is a transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. The drug is being co-developed with AbbVie (ABBV). Traditionally, CD71 hasn’t been a keen target given its expression on normal tissues and for potentially causing toxicities. The company presented data from their initial Phase 1 trial at ASCO 2020 that validated CD71 as a first-in-class oncology target with positive clinical activity observed. Currently, CytomX is advancing CX-2029 into 4 dose-expansion cohorts in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell lymphoma.
Source: January Presentation
On the clinical front, patient enrollment continues in the Phase 2 expansion study evaluating CX-2029 as a single agent in four cohorts: squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction cancers, and diffuse large B-cell lymphoma. Initial data from the CX-2029 Phase 2 expansion study is projected to be available in the fourth quarter of 2021; however, not all cohorts are expected to be ready by the end of 2021. Some of the cohorts, likely from the squamous lung and head and neck cohorts, should be available this year, but initial data from the additional cohorts are anticipated in 2022.
Analyst Commentary & Balance Sheet:
As of March 31st, 2021, CytomX Therapeutics had cash and cash equivalents of roughly $330 million. Additionally, the company had short-term investments of $64 million. Research and development expenses for Q1 were $22.3 million, compared to $42.8 million in Q1 of 2020. General and administrative expenses for Q1 of 2021 were $9.2 million, compared to $9.5 million in 2020. The company generated $15.9 million in revenue for the quarter ending March 31st, 2021, compared to $49.5 million in the same quarter of 2020. The lower revenue was the result of decreased revenue from AbbVie primarily related to the $40 million milestone payment earned in March 2020 associated with the CX-2029 project and a $10 million decrease in revenue from Bristol Myers Squibb for a milestone payment earned from the CTLA-4 program.
The decrease was partially offset by Astellas, which is from recognizing the upfront payment that is a part of their collaboration and license agreement. Overall, the company had a net loss of $15.5 million for the first quarter, compared to a net loss of $12.2 million in Q1 of 2020. The most recent capital raise came on January 20th, 2021. The company announced the pricing of a $100 million public offering of common stock that consisted of 14,285,714 shares at a price per share of $7.
This stock has mixed views on Wall Street. Over the past several months, JPMorgan ($14 price target) Jefferies and Mizuho Securities ($16 price target) have either upgraded or initiated the stock as a Buy. Two weeks ago, Barclays downgraded CTMX to a Hold with a $7 price target, however.
Verdict:
The company has made some progress since we last looked at it. That said pipeline development has moved slowly and analyst price targets are down slightly since we last revisited it. The company has more than ample cash on hand and a few shots on goal. I obviously like the strategic partnerships the company enjoys with larger players.
Initial data from the praluzatamab ravtansine (CX-2009) Phase 2 study in the fourth quarter of 2021.
Initial data from the CX-2029 Phase 2 expansion study in the fourth quarter of 2021.
IND submission for CX-904 in late 2021
There are some milestones but no major catalysts on the horizon in 2021 (summary above). Given that we are still years away from potential commercialization, CTMX can't be considered for a large holding. Given the cash balance of the firm, I would kind of like this name for a covered call candidate. Unfortunately, while options are available against this equity, the lack of liquidity makes this strategy non-viable. Therefore, we are passing on any investment recommendation on CTMX at this time.
Time doesn't wait for anyone, but you always have to wait for time.”― anonymous
Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum
Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.
This article was written by
Bret Jensen profile picture.
Bret Jensen
45.05K Followers
Author of
The Biotech Forum
Finding tomorrow's big winners in the lucrative biotech sector
http://www.bretjenseninvests.com
Specializing in biotech stocks, Small Caps, managing optimized portfolios
Contributor Since 2009
Checking In On CytomX Therapeutics
Jun. 13, 2021 5:01 AM ETCytomX Therapeutics, Inc. (CTMX)
Summary
Today, we revisit CytomX Therapeutics for our first in-depth look at this small oncology name since August of 2019.
The company is well funded at the moment, has strategic partnerships and a few 'shots on goal'.
A full investment analysis and recommendation follows in the paragraphs below.
I do much more than just articles at The Biotech Forum: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »
Set iv fluid intravenous drop saline drip hospital room,Medical Concept,treatment emergency and injection drug infusion care chemotherapy, concept.blue light background,selective focus stock photo
Amornrat Phuchom/iStock via Getty Images
It's easy finding reasons why other folks should be patient.”― George Eliot, Adam Bede
Today, we revisit a small oncology concern for the first time in over two and a half years. Given the time elapsed since out last in-depth look at this developmental firm, it was time for a new deep dive. A full analysis follows.
Company Overview:
CytomX Therapeutics (CTMX) is a San Francisco, California-based clinical-stage oncology-oriented biopharmaceutical company that IPO’d in 2015. The company’s pipeline is based around their Probody therapeutic design. Probody therapeutics seek to manipulate the tumor microenvironment to better localize treatment and limit the effect on healthy tissue. The therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment, and masked target-binding regions limit activity in healthy tissue. When the therapeutics encounter active proteases near a tumor, they remove their masks and bind to the tumor targets, ultimately turning the disease against itself.
Overall, this new therapeutic design can create or widen the therapeutic window, enable new combinations previously not possible due to toxicities, and expand the universe of drug targets. The pipeline of Probody therapeutics consists of 9 product candidates; however, the overall pipeline is in the early innings of development. The company’s two lead product candidates are CX-2009 and CX-2029. CytomX Therapeutics currently has a market capitalization of approximately $450 million and trades for just north of $7.00 a share.
Pipeline:
Source: January Presentation
CX-2009:
CX-2009 is a Probody drug conjugate that is conjugated with DM4, targeting CD166. CD166 is a molecule widely and highly expressed on solid tumor cells and in HER2 non-amplified breast cancer. Nearly 80% of breast cancer is HER2 non-amplified. CD166 was previously considered undruggable due to its expression on normal tissues. The drug is being tested as a monotherapy in ER/PR positive, HER2 negative breast cancer, and also as a combination therapy in triple-negative breast cancer. Breast cancer is the 2nd leading cause of cancer deaths in women. It’s estimated that breast cancer is 30% of all cancer in females with roughly 276,000 new cases a year in the United States. Furthermore, approximately 42,000 women die each year in the United States. In updated Phase 1 trial results, announced at ASCO in 2020, the drug demonstrated durable clinical activity in HER2 negative breast cancer.
Source: January Presentation
Clinical activity for the program continues to progress. CytomX began enrolling patients with human epidermal growth factor receptor 2 HER2-non-amplified breast cancer into a Phase 2 multi-cohort study evaluating CX-2009 as monotherapy, and as a combination treatment paired with CX-072, a conditionally activated anti-PD-L1 antibody, in patients with triple-negative breast cancer. Initial data from the CX-2009 Phase 2 study should be available in the fourth quarter of 2021.
Source: January Presentation
CX-2029:
CX-2029 is a PDC directed against CD71. CD71 is a transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. The drug is being co-developed with AbbVie (ABBV). Traditionally, CD71 hasn’t been a keen target given its expression on normal tissues and for potentially causing toxicities. The company presented data from their initial Phase 1 trial at ASCO 2020 that validated CD71 as a first-in-class oncology target with positive clinical activity observed. Currently, CytomX is advancing CX-2029 into 4 dose-expansion cohorts in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell lymphoma.
Source: January Presentation
On the clinical front, patient enrollment continues in the Phase 2 expansion study evaluating CX-2029 as a single agent in four cohorts: squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction cancers, and diffuse large B-cell lymphoma. Initial data from the CX-2029 Phase 2 expansion study is projected to be available in the fourth quarter of 2021; however, not all cohorts are expected to be ready by the end of 2021. Some of the cohorts, likely from the squamous lung and head and neck cohorts, should be available this year, but initial data from the additional cohorts are anticipated in 2022.
Analyst Commentary & Balance Sheet:
As of March 31st, 2021, CytomX Therapeutics had cash and cash equivalents of roughly $330 million. Additionally, the company had short-term investments of $64 million. Research and development expenses for Q1 were $22.3 million, compared to $42.8 million in Q1 of 2020. General and administrative expenses for Q1 of 2021 were $9.2 million, compared to $9.5 million in 2020. The company generated $15.9 million in revenue for the quarter ending March 31st, 2021, compared to $49.5 million in the same quarter of 2020. The lower revenue was the result of decreased revenue from AbbVie primarily related to the $40 million milestone payment earned in March 2020 associated with the CX-2029 project and a $10 million decrease in revenue from Bristol Myers Squibb for a milestone payment earned from the CTLA-4 program.
The decrease was partially offset by Astellas, which is from recognizing the upfront payment that is a part of their collaboration and license agreement. Overall, the company had a net loss of $15.5 million for the first quarter, compared to a net loss of $12.2 million in Q1 of 2020. The most recent capital raise came on January 20th, 2021. The company announced the pricing of a $100 million public offering of common stock that consisted of 14,285,714 shares at a price per share of $7.
This stock has mixed views on Wall Street. Over the past several months, JPMorgan ($14 price target) Jefferies and Mizuho Securities ($16 price target) have either upgraded or initiated the stock as a Buy. Two weeks ago, Barclays downgraded CTMX to a Hold with a $7 price target, however.
Verdict:
The company has made some progress since we last looked at it. That said pipeline development has moved slowly and analyst price targets are down slightly since we last revisited it. The company has more than ample cash on hand and a few shots on goal. I obviously like the strategic partnerships the company enjoys with larger players.
Initial data from the praluzatamab ravtansine (CX-2009) Phase 2 study in the fourth quarter of 2021.
Initial data from the CX-2029 Phase 2 expansion study in the fourth quarter of 2021.
IND submission for CX-904 in late 2021
There are some milestones but no major catalysts on the horizon in 2021 (summary above). Given that we are still years away from potential commercialization, CTMX can't be considered for a large holding. Given the cash balance of the firm, I would kind of like this name for a covered call candidate. Unfortunately, while options are available against this equity, the lack of liquidity makes this strategy non-viable. Therefore, we are passing on any investment recommendation on CTMX at this time.
Time doesn't wait for anyone, but you always have to wait for time.”― anonymous
Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum
Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.
This article was written by
Bret Jensen profile picture.
Bret Jensen
45.05K Followers
Author of
The Biotech Forum
Finding tomorrow's big winners in the lucrative biotech sector
http://www.bretjenseninvests.com
Specializing in biotech stocks, Small Caps, managing optimized portfolios
Contributor Since 2009
Sehe ich das richtig das noch ein Gap zwischen 5,1 und 5,95 USD offen ist?
Gestern nachgekauft zu 6.9 USD. Wieder eine ordentliche Portion Aktien. Schau ma mal...
Was man den Herren von Barclays bezahlt hat das habe ich mich auch schon gefragt. Die Analysten liegen in den meisten Fällen sowieso daneben und Ihre Trefferquote ist minimal, leider beeinflusst das die Kurse trotzdem.
Antwort auf Beitrag Nr.: 68.373.794 von Jerry_Maguire am 01.06.21 23:03:02Natürlich muss es heißen ... mit seinem 445 Mio USD nur 110 Mio USD über seinem Cashbestand notiert.
Gruß
JM
Gruß
JM
Durchsuchen
02.05.24 · wO Chartvergleich · Ansys |
02.05.24 · Sharedeals · CytomX Therapeutics |
12.03.24 · wO Chartvergleich · Blackbaud (Old) |